News

Exploratory Mindset Drives Insights at HLTH 2024: Black Book Poll Reveals Attendees Prioritizing Learning Over Immediate Investments

Survey reveals attendees are postponing AI and IT initiatives as budget constraints shift focus to internal system challenges, with unproven…

1 year ago

Global Health Exhibition Opens its Doors Tomorrow to Record-Breaking 100,000+ Attendees to World’s Premier Healthcare Transformation Event

Kingdom of Saudi Arabia opens the Global Health Exhibition (21-23 October 2024) tomorrow, a major international healthcare event with 100,000+…

1 year ago

Lena Esmail Advocates for Expanding Healthcare Access in Underserved Communities: A Call to Support QuickMed’s Innovative Approach

Lena Esmail is a healthcare innovator and the CEO of QuickMed, which she founded in 2018. YOUNGSTOWN, OH / ACCESSWIRE…

1 year ago

Kaia Health Appoints Adam Pellegrini as Global CEO And Launches The First Digital Pulmonary Rehab Program In Partnership With The COPD Foundation

NEW YORK, Oct. 19, 2024 /PRNewswire/ -- Kaia Health (Kaia), a leading digital health company, announces the appointment of Adam…

1 year ago

Investors in Common Stock and Certain Debt Securities Offered by Valeant Pharmaceuticals International, Inc. May be Entitled to Payment from an SEC Fair Fund

WASHINGTON, Oct. 19, 2024 /PRNewswire/ -- The following statement is being issued regarding the Valeant Pharmaceuticals Fair Fund. UNITED STATES SECURITIES…

1 year ago

New Clinical Study Confirms the Industry Leading Performance Of Senzime’s TetraGraph System

UPPSALA, SWEDEN / ACCESSWIRE / October 19, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Philadelphia, ANESTHESIOLOGY 2024 - A just published US-based study…

1 year ago

KFSHRC Pioneers Cancer Treatment with Breakthrough Therapies and Exceptional Outcomes

RIYADH, Saudi Arabia, Oct. 19, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is revolutionizing cancer…

1 year ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing…

1 year ago

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…

1 year ago